Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene ...

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene ...

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD

Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMD

Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-label, dose-escalation clinical trial in the US will assess the safety, tolerability and efficacy of KH658 as a single suprachoroidal space administration of gene therapy for patients with previously …

Case 1: Managing Suboptimal Response in Bilateral nAMD: Transitioning From Biosimilars to High-Dose Aflibercept for Durable Drying

A panelist discusses how a woman aged 74 years with neovascular age-related macular degeneration (nAMD) showed improved disease control and vision in her right eye after switching from ranibizumab to a high-dose aflibercept (8 mg) treatment that successfully extended intervals to 10 weeks.